NasVax Ltd. (TASE: NSVX), which develops immunization technologies, announced to the Tel Aviv Stock Exchange this morning that the results of a trial on animals of a vaccine against swine flu were positive.
The company said it had successfully completed an initial trial that examined the use of its VaxiSome technology in immunizing against the H1N1 virus through intramuscular injection.
The trial was carried out on 72 mice that were divided into control groups and injected with the appropriate antigen. The trial results showed that the combination of the antigen with NasVax’s technology caused a rise in the level of antibodies in comparison with groups that received the antigen only.
NasVax will now have to carry out larger trials of its technology with the H1N1 antigen on animals, and, assuming that these trials are successful, to obtain the necessary regulatory approval for performing trials on human beings.
Even if such approvals are received, and the company estimates that this will take a long time, the trials will require considerable investment. Moreover, there is no certainty that trials will be successful in a way that will enable commercial use of the technology on human beings or that approval will be granted for that purpose.
Published by Globes [online], Israel business news - www.globes.co.il - on October 12, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009